^
    Apply
    A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung) (NCT03337698)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/27/2017
    Primary completion :
    09/30/2025
    Completion :
    11/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (NCT05286801)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/17/2022
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    TNFA • SMARCB1
    |
    SMARCA4 mutation
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (NCT04524871)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    11/01/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PD-L1
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • IO-108 • NKT2152 • SAR439459 • muzastotug (ADG126) • tobemstomig (RG6139)
    Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). (NCT05681039)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/02/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2026
    PD-L1 • CD4
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • tiragolumab (RG6058)
    A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (SKYSCRAPER-05) (NCT04832854)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    04/23/2021
    Primary completion :
    03/05/2025
    Completion :
    03/05/2025
    PD-L1
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine • paclitaxel • pemetrexed • tiragolumab (RG6058)
    Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (NCT04958811)
    Phase 2
    Georgetown University
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/21/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    ALK • ROS1
    |
    PD-L1 expression • ALK wild-type • ROS1 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (MORPHEUS-PDAC) (NCT03193190)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/05/2017
    Primary completion :
    02/28/2025
    Completion :
    02/28/2025
    PD-L1
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (NCT05645692)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/13/2023
    Primary completion :
    12/30/2026
    Completion :
    12/30/2026
    PD-L1
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC (AFT-57) (NCT05798663)
    Phase 2
    Alliance Foundation Trials, LLC.
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/07/2023
    Primary completion :
    08/01/2025
    Completion :
    10/01/2027
    PD-L1
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (MORPHEUS mUC) (NCT03869190)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    01/03/2025
    Initiation :
    06/01/2019
    Primary completion :
    10/03/2024
    Completion :
    05/21/2026
    PD-L1
    |
    cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)
    A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) (NCT06331598)
    Phase 2
    Hoffmann-La Roche
    Withdrawn
    Last update posted :
    12/24/2024
    Initiation :
    11/30/2024
    Primary completion :
    10/20/2028
    Completion :
    09/20/2029
    TMB • MSI
    |
    TMB-H • MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) (NCT05459129)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    04/13/2023
    Primary completion :
    08/11/2024
    Completion :
    08/11/2024
    PD-L1 • CD4
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • tiragolumab (RG6058)
    Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial (NCT05715281)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    09/26/2023
    Primary completion :
    10/15/2026
    Completion :
    10/15/2026
    SMARCB1
    |
    SMARCA4 mutation
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma (NCT03784326)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    02/19/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PD-L1
    |
    Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • tiragolumab (RG6058) • fluorouracil topical
    Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP) (NCT06003621)
    Phase 2
    Omico
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    12/15/2023
    Primary completion :
    05/01/2026
    Completion :
    11/01/2028
    PD-L1 • TMB • CD8 • CD4
    |
    PD-L1 expression • PD-L1 amplification
    |
    Tecentriq (atezolizumab) • Pegasys (pegylated interferon α -2a) • tiragolumab (RG6058)
    Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma (NeoACTIVATE) (NCT03554083)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    05/24/2024
    Initiation :
    10/05/2018
    Primary completion :
    06/29/2025
    Completion :
    06/29/2025
    PD-L1 • BRAF
    |
    BRAF V600 • BRAF wild-type
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib) • tiragolumab (RG6058)
    A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06) (NCT04619797)
    Phase 2/3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    12/14/2020
    Primary completion :
    05/14/2027
    Completion :
    05/14/2027
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)
    A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03) (NCT04513925)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    08/24/2020
    Primary completion :
    10/30/2024
    Completion :
    12/30/2027
    PD-L1
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Imfinzi (durvalumab) • tiragolumab (RG6058)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (NCT05116202)
    Phase 1/2
    Hoffmann-La Roche
    Completed
    Last update posted :
    05/01/2024
    Initiation :
    02/02/2022
    Primary completion :
    09/22/2023
    Completion :
    03/27/2024
    CD4
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (MORPHEUS-EC) (NCT03281369)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    05/01/2024
    Initiation :
    10/13/2017
    Primary completion :
    08/24/2024
    Completion :
    04/30/2025
    HER-2 • PD-L1 • TIGIT
    |
    HER-2 negative • HER-2 expression
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
    A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (CITYSCAPE) (NCT03563716)
    Phase 2
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    08/10/2018
    Primary completion :
    06/30/2019
    Completion :
    03/31/2025
    PD-L1
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) (NCT04665843)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/02/2021
    Primary completion :
    09/20/2023
    Completion :
    10/02/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) (NCT04294810)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    04/12/2024
    Initiation :
    03/04/2020
    Primary completion :
    02/21/2025
    Completion :
    02/21/2025
    PD-L1
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor (NCT03977467)
    Phase 2
    SCRI Development Innovations, LLC
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    08/30/2019
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    PD-L1
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (NCT05251948)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    04/03/2024
    Initiation :
    03/01/2022
    Primary completion :
    12/31/2024
    Completion :
    06/22/2025
    HER-2
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab) • capecitabine • oxaliplatin • tiragolumab (RG6058)
    Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN) (NCT05483400)
    Phase 2
    University Medical Center Groningen
    Recruiting
    Last update posted :
    01/12/2024
    Initiation :
    10/18/2023
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    CD8
    |
    CDKN2A negative
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (NCT05259319)
    Phase 1
    Centre Georges Francois Leclerc
    Recruiting
    Last update posted :
    10/17/2023
    Initiation :
    12/05/2022
    Primary completion :
    12/05/2024
    Completion :
    12/05/2024
    EGFR • BRAF
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (NCT05746481)
    Phase 2
    Liza Villaruz, MD
    Recruiting
    Last update posted :
    08/10/2023
    Initiation :
    08/08/2023
    Primary completion :
    09/30/2025
    Completion :
    04/30/2027
    PD-L1 • CD4
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058) • Pemfexy (pemetrexed)
    A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer (NCT04584112)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/15/2023
    Initiation :
    09/28/2020
    Primary completion :
    03/08/2023
    Completion :
    03/08/2023
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative • PGR expression
    |
    Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • tiragolumab (RG6058) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous • doxorubicin liposomal
    Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer (SKYROCKET) (NCT05034055)
    Phase 2
    Yonsei University
    Not yet recruiting
    Last update posted :
    09/03/2021
    Initiation :
    12/01/2021
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    PD-L1
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)